Company & Sponsor Intelligence
Seaside Therapeutics, Inc.
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials4
Recruiting0
Completed3
Countries1
Therapeutic footprint
autismneurodevelopmental_other
Indexed studies
NCT01064973An Open Label Extension Study of STX209 in Subjects With Autism Spectrum Disorders
autism · United StatesPHASE2
autism · United StatesPHASE2
NCT00788073Safety, Tolerability and Efficacy Study of STX209 in Subjects With Fragile X Syndrome
neurodevelopmental_other · United StatesPHASE2
neurodevelopmental_other · United StatesPHASE2
NCT01325220Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome
neurodevelopmental_other · United StatesPHASE3
neurodevelopmental_other · United StatesPHASE3
NCT00892580Biomarker and DNA Collection in Subjects Participating in Protocol 22003
neurodevelopmental_other · United StatesCOMPLETED
neurodevelopmental_other · United StatesCOMPLETED
Intelligence layer updated: 2026-10-11 23:31:09.606883+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →